Cytomorphological and histomorphological features of lung adenocarcinoma with epidermal growth factor receptor mutation and anaplastic lymphoma kinase gene rearrangement

Gardić,Nikola; Lovrenski,Aleksandra; Sekeruš,Vanesa; Lečić,Svetlana Kašiković; Bijelović,Milorad; Lakić,Tanja; Ilić,Aleksandra; Zarić,Bojan; Glumac,Sofija

doi:10.3892/ol.2024.14786

Cytomorphological and histomorphological features of lung adenocarcinoma with epidermal growth factor receptor mutation and anaplastic lymphoma kinase gene rearrangement

Authors:
- Nikola Gardić
- Aleksandra Lovrenski
- Vanesa Sekeruš
- Svetlana Kašiković Lečić
- Milorad Bijelović
- Tanja Lakić
- Aleksandra Ilić
- Bojan Zarić
- Sofija Glumac
View Affiliations

Affiliations: Department of Pathology, Faculty of Medicine, University of Novi Sad, Novi Sad 21000, Serbia, Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica 21204, Serbia, Institute of Pathology, Faculty of Medicine, University of Belgrade, Belgrade 11000, Serbia
Published online on: November 4, 2024 https://doi.org/10.3892/ol.2024.14786
Article Number: 40
Copyright: © Gardić et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is among the lethal and most prevalent oncological diseases globally. It is known that two types of mutations, namely anaplastic lymphoma kinase (ALK) gene rearrangement and epidermal growth factor receptor (EGFR) gene mutation, are responsible for the development of lung adenocarcinoma. The present study aimed to investigate the differences in the frequency of clinical, cytomorphological and histomorphological features of ALK and EGFR‑positive lung adenocarcinomas. The present retrospective study comprised 101 patients diagnosed with lung adenocarcinoma. Based on the molecular findings, the patients were categorized into three groups as follows: The ALK‑rearranged group (n=28), the EGFR group (n=42) and the negative group (n=31). The clinical features analyzed included sex, age, smoking status and disease stage. The cytomorphological and histomorphological features examined encompassed the following: Cell cluster size, the arrangement of tumor cells, the size of nuclei, nuclear atypia, the visibility of nucleoli, the presence of necrosis, intracytoplasmic vacuoles, signet ring cells, stromal characteristics and the presence of inflammatory infiltrate presence. The results indicated that the female sex was more prevalent in the EGFR group, but statistically significant differences (P<0.05) were observed between the EGFR and negative group. A significantly greater percentage of non‑smokers was identified in the EGFR group compared with the ALK group (P<0.01). The majority of patients with confirmed ALK or EGFR mutations received onco‑specific treatment. Focal and abundant necrosis was significantly less common in cytological samples in the EGFR group than in the other groups (21.43 vs. 57.14 and 51.61%, combined, P<0.01). No significant differences were observed in other cytomorphological features between the groups. Intracytoplasmic vacuoles, signet ring cells and cells with visible nucleoli were significantly more frequent in histological specimens of the ALK group (P<0.01). The predictive model composed of these features or combined with sex and smoking habits exhibited statistically significant differences for mutation status as a criterion (P<0.01). Collectively, the findings of the present study confirmed that, in addition to clinical characteristics, certain cytological and histological features of lung adenocarcinoma are associated with the mutational status of the tumor.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Bade BC and Dela Cruz CS: Lung cancer 2020: Epidemiology, etiology, and prevention. Clin Chest Med. 41:1–24. 2020. View Article : Google Scholar : PubMed/NCBI
3	Šutić M, Vukić A, Baranašić J, Försti A, Džubur F, Samaržija M, Jakopović M, Brčić L and Knežević J: Diagnostic, predictive, and prognostic biomarkers in non-small cell lung cancer (NSCLC) management. J Pers Med. 11:11022021. View Article : Google Scholar
4	Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, Dacic S, Jain D, Kerr KM, Lantuejoul S, et al: The 2021 WHO classification of lung tumors: Impact of advances since 2015. J Thorac Oncol. 17:362–387. 2022. View Article : Google Scholar : PubMed/NCBI
5	Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina H, Hatanaka H, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
6	Jiang F, Wang C, Yang P, Sun P and Liu J: Pathological cytomorphologic features and the percentage of ALK FISH-positive cells predict pulmonary adenocarcinoma prognosis: A prospective cohort study. World J Surg Oncol. 19:2782021. View Article : Google Scholar : PubMed/NCBI
7	Hofman P: ALK in non-small cell lung cancer (NSCLC) pathobiology, epidemiology, detection from tumor tissue and algorithm diagnosis in a daily practice. Cancers. 9:1072017. View Article : Google Scholar : PubMed/NCBI
8	Miyata K, Morita S, Dejima H, Seki N, Matsutani N, Mieno M, Kondo F, Soejima Y, Tanaka F and Sawabe M: Cytological markers for predicting ALK-positive pulmonary adenocarcinoma. Diagn Cytopathol. 45:963–970. 2017. View Article : Google Scholar : PubMed/NCBI
9	Yoshida A, Tsuta K, Nakamura H, Kohno T, Takahashi F, Asamura H, Sekine I, Fukayama M, Shibata T, Furuta K and Tsuda H: Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol. 35:1126–1134. 2011. View Article : Google Scholar
10	Nishino M, Klepeis VE, Yeap BY, Bergethon K, Morales-Oyarvide V, Dias-Santagata D, Yagi Y, Mark EJ, Iafrate AJ and Mino–Kenudson M: Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas. Mod Pathol. 25:1462–1472. 2012. View Article : Google Scholar : PubMed/NCBI
11	Pareja F, Crapanzano JP, Mansukhani MM, Bulman WA and Saqi A: Cytomorphological features of ALK-positive lung adenocarcinomas: Psammoma bodies and signet ring cells. Cancer Cytopathol. 123:162–170. 2015. View Article : Google Scholar : PubMed/NCBI
12	Ha SY, Ahn J, Roh MS, Han J, Lee JJ, Lee B and Yim J: Cytologic features of ALK-positive pulmonary adenocarcinoma. Korean J Pathol. 47:252–257. 2013. View Article : Google Scholar : PubMed/NCBI
13	Russo A, Franchina T, Riccardi GRR, Picone A, Ferraro G, Zanghi M, Toscano G, Giordano A and Adamo V: A decade of EGFR inhibition in EGFR-mutated non-small cell lung cancer (NSCLC): Old successes and future perspectives. Oncotarget. 6:26814–26825. 2015. View Article : Google Scholar : PubMed/NCBI
14	Sharma S, Gupta N, Singh N, Chaturvedi R, Behera D and Rajwanshi A: Cytomorphological features as predictors of epidermal growth factor receptor mutation status in lung adenocarcinoma. Cytojournal. 15:112018. View Article : Google Scholar : PubMed/NCBI
15	Dacic S, Shuai Y, Yousem S, Ohori P and Nikiforova M: Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Mod Pathol. 23:159–168. 2010. View Article : Google Scholar : PubMed/NCBI
16	Hu H, Pan Y, Li Y, Wang L, Wang R, Zhang Y, Li H, Ye T, Zhang Y, Luo X, et al: Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma. Onco Targets Ther. 7:1423–1437. 2014. View Article : Google Scholar : PubMed/NCBI
17	Kobayashi Y, Yokose T, Kawamura K, Iwasaki S, Murata Y, Onuma S, Hasebe T, Nagai K, Sasaki S and Ochiai A: Cytologic factors associated with prognosis in patients with peripheral adenocarcinoma of the lung measuring 3 cm or less in greatest dimension. Cancer. 105:44–51. 2005. View Article : Google Scholar : PubMed/NCBI
18	Ravaioli S, Bravaccini S, Tumedei MM, Pironi F, Candoli P and Puccetti M: Easily detectable cytomorphological features to evaluate during ROSE for rapid lung cancer diagnosis: From cytology to histology. Oncotarget. 8:11199–11205. 2017. View Article : Google Scholar : PubMed/NCBI
19	Radić J, Nikolić I, Kolarov-Bjelobrk I, Vasiljević T, Djurić A, Vidović V and Kožik B: Prognostic and predictive significance of primary tumor localization and HER2 expression in the treatment of patients with KRAS wild-type metastatic colorectal cancer: Single-centre experience from serbia. J Pers Med. 14:8792024. View Article : Google Scholar : PubMed/NCBI
20	Marotti JD, Schwab MC, McNulty NJ, Rigas JR, DeLong PA, Memoli VA, Tsongalis GJ and Padmanabhan V: Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: A retrospective review of 50 cases. Diagn Cytopathol. 41:15–21. 2013. View Article : Google Scholar : PubMed/NCBI
21	Noronha V, Ramaswamy A, Patil VM, Joshi A, Chougule A, Kane S, Kumar R, Sahu A, Doshi V, Nayak L, et al: ALK positive lung cancer: clinical profile, practice and outcomes in a developing country. PLoS One. 11:e01607522016. View Article : Google Scholar : PubMed/NCBI
22	Hou X, Chen H, Liu Y, Gong S, Zhudai M and Shen L: Clinicopathological and computed tomography features of patients with early-stage non-small-cell lung cancer harboring ALK rearrangement. Cancer Imaging. 23:202023. View Article : Google Scholar : PubMed/NCBI
23	Kang HJ, Lim HJ, Park JS, Cho YJ, Yoon HI, Chung JH, Lee JH and Lee CT: Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma. Respir Med. 108:388–394. 2014. View Article : Google Scholar : PubMed/NCBI
24	Liu Q, Huang Q, Yu Z and Wu H: Clinical characteristics of non-small cell lung cancer patients with EGFR mutations and ALK&ROS1 fusions. Clin Respir J. 16:216–225. 2022. View Article : Google Scholar : PubMed/NCBI
25	Zhou JY, Zheng J, Yu ZF, Xiao WB, Zhao J, Sun K, Wang B, Chen X, Jiang LN, Ding W and Zhou JY: Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations. Eur Radiol. 25:1257–1266. 2015. View Article : Google Scholar : PubMed/NCBI
26	Mourabiti AY, Sqalli Houssaini M, Benfares A, Bouardi NE, Lamrani MYA, Fatemi HE, Serraj M, Amara B, Qjidaa H, Smahi M, et al: Clinical and radiological features associated with EGFR mutation in non-small-cell lung cancer: A study of 149 cases. Egypt J Radiol Nucl Med. 54:1712023. View Article : Google Scholar
27	Tsuta K, Ishii G, Yoh K, Nitadori J-I, Hasebe T, Nishiwaki Y, Endoh Y, Kodama T, Nagai K and Ochiai A: Primary lung carcinoma with signetring cell carcinoma components: Clinicopathological analysis of 39 cases. Am J Surg Pathol. 28:868–874. 2004. View Article : Google Scholar : PubMed/NCBI
28	Boland JM, Wampfler JA, Jang JS, Wang X, Erickson–Johnson MR, Oliveira AM, Yang P, Jen J and Yi ES: Pulmonary adenocarcinoma with signet ring cell features: A comprehensive study from 3 distinct patient cohorts. Am J Surg Pathol. 38:1681–1688. 2014. View Article : Google Scholar : PubMed/NCBI
29	Miyata-Morita K, Morita S, Matsutani N, Kondo F, Soejima Y and Sawabe M: Frequent appearance of club cell (Clara cell)-like cells as a histological marker for ALK-positive lung adenocarcinoma. Pathol Int. 69:688–696. 2019. View Article : Google Scholar : PubMed/NCBI
30	Blons H, Côté JF, Le Corre D, Riquet M, Fabre-Guilevin E, Laurent-Puig P and Danel C: Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation. Am J Surg Pathol. 30:1309–1315. 2006. View Article : Google Scholar : PubMed/NCBI
31	Song Z, Liu T, Shi L, Yu Z, Shen Q, Xu M, Huang Z, Cai Z, Wang W, Xu C and Sun J: The deep learning model combining CT image and clinicopathological information for predicting ALK fusion status and response to ALK-TKI therapy in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 48:361–371. 2021. View Article : Google Scholar : PubMed/NCBI